Immunization with WT1-derived peptides by tattooing inhibits the growth of TRAMP-C2 prostate tumor in mice.
The expression of the transcription factor encoded by the Wilms tumor gene 1 (WT1) is associated with a variety of human cancers. WT1 protein has been reported to serve as a target antigen for tumor-specific immune responses. We observed that the immunization of mice with peptide vaccines derived from WT1 in a mixture with the CpG adjuvant (ODN 1826) by tattoo administration was superior to subcutaneous delivery of the peptides in combination with CpG formulated with the mineral oil adjuvant or a DNA vaccine or a recombinant vaccinia virus vaccine expressing the truncated WT1 protein. Tattooing with the WT1122-140 and WT1126-134 peptide elicited the response of WT1-specific interferon-γ-producing T cells. Peptide vaccine administered with a tattoo device had an antitumor effect on the growth of the prostate tumor cell line TRAMP-C2, provided that the transforming growth factor-β produced by tumor cells was neutralized by anti-TGFβ monoclonal antibody. The treatment of the tumor-bearing mice with 5-azadeoxycytidine or poly IC did not work in synergy with the peptide vaccine.
Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague 2, Czech Republic.
Katarina
K
Babiarova
Luda
L
Kutinova
Kamila
K
Zurkova
Jitka
J
Krystofova
Eva
E
Brabcova
Petr
P
Hainz
Jan
J
Musil
Sarka
S
Nemeckova
D000276:Adjuvants, Immunologic; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001374:Azacitidine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000008:administration & dosage*; D045744:Cell Line, Tumor; D000077209:Decitabine; D007271:Injections, Intradermal; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D011070:Poly I-C / Q000494:pharmacology / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000628:therapy*; D013653:Tattooing; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors / Q000276:immunology; D022223:Vaccines, Subunit / Q000008:administration & dosage; D025721:WT1 Proteins / Q000008:administration & dosage / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D016212:Transforming Growth Factor beta; D022223:Vaccines, Subunit; D025721:WT1 Proteins; D000077209:Decitabine; D001374:Azacitidine; D011070:Poly I-C